Angiotensin I
Lokelma for the treatment of adults with hyperkalaemia: approved in European Union
The European Commission has granted marketing authorisation for Lokelma ( formerly ZS-9, sodium Zirconium cyclosilicate ) for the treatment of...
CHAMP-HF Registry: medical therapy for heart failure with reduced ejection fraction
Guidelines strongly recommend patients with heart failure with reduced ejection fraction ( HFrEF ) be treated with multiple medications proven...
LCZ696, a combination of Sacubitril and Valsartan, has a cardio-protective effect against myocardial infarction
The new drug LCZ696 is a treatment for chronic heart failure. LCZ696 is better than conventional drugs at reducing cardiac...
Heart failure and reduced ejection fraction: Sacubitril associated with Valsartan over angiotensin-converting enzyme inhibitors
The quality of evidence regarding patient-centered outcomes in adults with heart failure after Sacubitril combined with Valsartan ( Entresto )...
ESC Guidelines on acute and chronic heart failure: Entresto included for the first time and new heart failure category added
European Society of Cardiology ( ESC ) Guidelines for the diagnosis and treatment of acute and chronic heart failure are...
FDA strengthens kidney warnings for diabetes medicines Canagliflozin and Dapagliflozin
The FDA ( Food and Drug Administration ) has strengthened the existing warning about the risk of acute kidney injury...
Empagliflozin significantly reduces the risk of progressive kidney disease in adults with type 2 diabetes with established cardiovascular disease
New data showed Empagliflozin ( Jardiance ) reduces the risk for new-onset or worsening kidney disease by 39% versus placebo...
RESPONSIfVE trial: effectiveness and tolerability of Ivabradine with or without concomitant beta-blocker therapy in patients with chronic stable angina
In the prospective, open-label, non-interventional, multicenter RESPONSIfVE study, the effectiveness, response rates and tolerability of Ivabradine ( Corlentor, Procoralan )...
Efficacy of Sacubitril / Valsartan relative to a prior decompensation
A study assessed whether the benefit of Sacubitril / Valsartan ( Entresto ) therapy varied with clinical stability. Despite the benefit...
ACE-inhibitor-induced angioedema: time to complete resolution of edema shorter with Icatibant than with combination therapy with glucocorticoid and antihistamine
Angioedema induced by treatment with angiotensin-converting-enzyme ( ACE ) inhibitors accounts for one third of angioedema cases in the emergency...
Hypertension in patients with diabetes mellitus: goal and treatment
Hypertension is a common diabetes comorbidity that affects the majority of patients, with the prevalence depending on type of diabetes,...
Heart failure: elevated plasma B-type natriuretic peptide concentrations inhibit circulating neprilysin activity
A study sought to hypothesize that elevated B-type natriuretic peptide ( BNP ) could act as an endogenous neprilysin inhibitor. A...
Angiotensin-receptor-neprilysin inhibitor vs ACE inhibitor: Valsartan / Sacubitril superior to Enalapril in reducing both sudden cardiac deaths and deaths from worsening heart failure in HF patients
The angiotensin-receptor-neprilysin inhibitor ( ARNI ) Valsartan / Sacubitril ( Entresto; LCZ696 ) reduced cardiovascular deaths and all-cause mortality compared...
Type 2 diabetes is a strong mortality predictor in men and women with heart failure
A study has tested the hypothesis that risk factor pattern, treatment and prognosis differ between men and women with heart...
FDA approves Veltassa, a new drug to treat hyperkalemia
The FDA ( Food and Drug Administration ) has approved Veltassa ( Patiromer for oral suspension ) to treat hyperkalemia,...
Angiotensin-converting enzyme inhibitors and receptor blockers were associated with significant lower incidence of appropriate ICD shock in patients with cardiomyopathy
Sudden cardiac death ( SCD ) is a leading cause of mortality in patients with cardiomyopathy. Although angiotensin-converting enzyme inhibitors...
Heart failure treatment: Entresto has shown to reduce the risk of cardiovascular death and hospitalization
Entresto ( Sacubitril / Valsartan ), previously known as LCZ696 has been approved by Health Canada for the treatment of...
Heart failure and reduced ejection fraction: Entresto cuts 30-day hospital readmissions
A post-hoc analysis of PARADIGM-HF data has demonstrated that fewer heart failure patients with reduced ejection fraction ( HFrEF...
Symptomatic chronic heart failure with reduced ejection fraction: Entresto has received EU approval
The European Commission ( EC ) has approved Entresto ( Sacubitril / Valsartan ) for the treatment of adult patients...
Entresto, a first-in-class angiotensin receptor neprilysin inhibitor: safety and efficacy in patients with hypertension and renal dysfunction
A 8-week, multicenter, open-label study has assessed the safety and efficacy of LCZ696 ( Entresto ), a first-in-class angiotensin receptor...